Development of an EGFRvIII specific recombinant antibody

BMC Biotechnology

Volumn 10, Issue , 2010, Pages

  Gupta, Puja ^a   Han, Shuang Yin ^a,b   Holgado Madruga, Marina ^a   Mitra, Siddhartha S ^a   Li, Gordon ^a   Nitta, Ryan T ^a   Wong, Albert J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL LINES; CELLULAR DOMAIN; CROSS REACTIVITY; DIAGNOSTIC MARKERS; DIAGNOSTIC TOOLS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA MULTIFORME; GLYCINE RESIDUES; HIGH QUALITY; HUMAN TUMORS; IMMUNOHISTOCHEMISTRY; IN-VIVO; NON-SMALL CELL LUNG CARCINOMATA; NORMAL TISSUE; POLYCLONAL ANTIBODY; PROSTATE CANCERS; RECOMBINANT ANTIBODY; RESEARCH REAGENTS; SINGLE-CHAIN FV; WESTERN BLOTS; WILD TYPES;

ASSAYS; CELL CULTURE; MONOCLONAL ANTIBODIES; RESEARCH LABORATORIES; TUMORS;

AMINO ACIDS;

CDRH2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G1; PHENYLALANINE; PROTEIN; RECOMBINANT ANTIBODY; RECOMBINANT EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TYROSINE; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; EPITOPE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN EXPRESSION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNOLOGY; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

ANIMALS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CROSS REACTIONS; EPITOPES; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS, EXPERIMENTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 77957370161     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-10-72     Document Type: Article

References (45)

1. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD, Weiner LM. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993, 53(14):3217-3220.
2. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Ogunbiyi JO, Shittu OB, Terry TR, Okeke LI, Wong AJ, Habib FK. A variant epidermal growth factor receptor protein is similarly expressed in benign hyperplastic and carcinomatous prostatic tissues in black and white men. West Afr J Med 2007, 26(1):42-47.
3. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci USA 1987, 84(19):6899-6903. 10.1073/pnas.84.19.6899, 299192, 3477813.
4. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313(5998):144-147. 10.1038/313144a0, 2981413.
5. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992, 89(10):4309-4313. 10.1073/pnas.89.10.4309, 49071, 1584765.
6. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995, 55(14):3140-3148.
7. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 2002, 98(3):357-361. 10.1002/ijc.10224, 11920586.
8. Luo X, Gong X, Tang CK. Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. Int J Cancer 2003, 104(6):716-721. 10.1002/ijc.11007, 12640678.
9. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003, 94(1):50-56. 10.1111/j.1349-7006.2003.tb01351.x, 12708474.
10. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004, 63(7):700-707.
11. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 2005, 27(2):317-325.
12. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003, 9(11):4247-4254.
13. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995, 55(23):5536-5539.
14. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ, Hale LP, Small C, Dranoff G, Friedman AH, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 2000, 97(13):7503-7508. 10.1073/pnas.130166597, 16575, 10852962.
15. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005, 11(4):1462-1466. 10.1158/1078-0432.CCR-04-1737, 15746047.
16. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990, 87(21):8602-8606. 10.1073/pnas.87.21.8602, 55005, 2236070.
17. Humphrey PA, Gangarosa LM, Wong AJ, Archer GE, Lund-Johansen M, Bjerkvig R, Laerum OD, Friedman HS, Bigner DD. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun 1991, 178(3):1413-1420. 10.1016/0006-291X(91)91051-D, 1678600.
18. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992, 89(7):2965-2969. 10.1073/pnas.89.7.2965, 48784, 1557402.
19. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004, 102(1):37-46. 10.1016/j.pharmthera.2004.01.002, 15056497.
20. Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 1997, 57(8):1419-1424.
21. Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 2009,
22. Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev 1999, 18(4):451-464. 10.1023/A:1006354102377, 10855788.
23. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008, 20(5):267-275. 10.1016/j.smim.2008.04.001, 2633865, 18539480.
24. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 2008, 339(1):74-81. 10.1016/j.jim.2008.08.004, 18775433.
25. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001, 61(12):4750-4755.
26. Langmuir VK, Mendonca HL, Woo DV. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 1992, 52(17):4728-4734.
27. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 2003, 100(2):639-644. 10.1073/pnas.232686499, 141049, 12515857.
28. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M. Single-chain antigen-binding proteins. Science 1988, 242(4877):423-426. 10.1126/science.3140379, 3140379.
29. Beers R, Chowdhury P, Bigner D, Pastan I. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 2000, 6(7):2835-2843.
30. Patel D, Lahiji A, Patel S, Franklin M, Jimenez X, Hicklin DJ, Kang X. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 2007, 27(5A):3355-3366.
31. Landry RC, Klimowicz AC, Lavictoire SJ, Borisova S, Kottachchi DT, Lorimer IA, Evans SV. Antibody recognition of a conformational epitope in a peptide antigen: Fv-peptide complex of an antibody fragment specific for the mutant EGF receptor, EGFRvIII. J Mol Biol 2001, 308(5):883-893. 10.1006/jmbi.2001.4628, 11352579.
32. Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, Rothacker J, Nice EC, Walker F, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004, 279(29):30375-30384. 10.1074/jbc.M401218200, 15075331.
33. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 1985, 77(2):305-319. 10.1016/0022-1759(85)90044-4, 3981007.
34. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997, 57(18):4130-4140.
35. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997, 15(2):159-163. 10.1038/nbt0297-159, 9035142.
36. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998, 16(7):677-681. 10.1038/nbt0798-677, 9661204.
37. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996, 9(7):617-621. 10.1093/protein/9.7.617, 8844834.
38. Robinson MK, Weiner LM, Adams GP. Improving Monoclonal Antibodies For Cancer Therapy. Drug Development research 2004, 61:172-187.
39. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990, 31(7):1191-1198.
40. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 1989, 49(20):5656-5663.
41. Van Osdol W, Fujimori K, Weinstein JN. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res 1991, 51(18):4776-4784.
42. Robinson MK, Weiner LM, Adams GP. Improving Monoclonal Antibodies For Cancer Therapy. Drug Development research 2004, 61:172-187.
43. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintainenece of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci USA 2010, 107(6):2616-21. 10.1073/pnas.0914356107, 2823874, 20133782.
44. Weiner LM. Bispecific antibodies in cancer therapy. Cancer J 2000, 6(Suppl 3):S265-271.
45. Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 2004, 279(52):53907-53914. 10.1074/jbc.M407888200, 15471859.